1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 18, 06/May/2021
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

The World Health Organization (WHO) lists human leishmaniasis as a neglected tropical disease; it is not under surveillance at European level.

Aim

We present surveillance data for visceral (VL) and cutaneous (CL) leishmaniasis for the period 2004 to 2018 in Greece to assess their public health importance.

Methods

We extracted data from the mandatory notification system to analyse separately imported and domestic cases of VL and CL. A case was defined by clinical manifestations compatible with VL or CL and laboratory confirmation.

Results

Between 2004 and 2018, 881 VL (862 domestic, 19 imported) and 58 CL cases (24 domestic, 34 imported) were recorded. The mean annual notification rate of domestic VL was 0.5 per 100,000 (range: 0.12–1.43/100,000) with a statistically significant increasing trend (p = 0.013). Cases were reported by all regions. The highest notification rate occurred in the age group 0–4 years (1.3/100,000). Overall 24% (164/680) of the cases were immunocompromised and their proportion increased after 2010 (p < 0.001). The mean annual notification rate of domestic CL was 0.05 per 100,000 (range: 0.01–0.19/100,000) with the highest rate in the age group 5–14 years (0.03/100,000). Cases were recorded in six of the 13 regions. Among 34 imported CL cases, 29 were foreign nationals.

Conclusion

VL is endemic in Greece, with an increasing trend and a considerable burden of severe disease and young children being most affected. CL is rarely reported. A sustainable action plan is needed to reduce the burden of VL and prevent local transmission of CL.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.18.2000159
2021-05-06
2024-12-03
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.18.2000159
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/18/eurosurv-26-18-3.html?itemId=/content/10.2807/1560-7917.ES.2021.26.18.2000159&mimeType=html&fmt=ahah

References

  1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.  https://doi.org/10.1371/journal.pone.0035671  PMID: 22693548 
  2. Centers for Disease Control and Prevention (CDC). Leishmaniasis: Disease. Atlanta: CDC. [Accessed 7 Feb 2020]. Available from: http://www.cdc.gov/parasites/leishmaniasis/disease.html
  3. Heymann D, MD. Control of Communicable Diseases Manual. 20thEdition. Washington, D.C: American Public Health Association. 2015; p342-5.
  4. Centers for Disease Control and Prevention (CDC). Leishmaniasis: Biology. Atlanta: CDC. [Accessed 7 Feb 2020]. Available from: http://www.cdc.gov/parasites/leishmaniasis/ biology.html.
  5. Ntais P, Sifaki-Pistola D, Christodoulou V, Messaritakis I, Pratlong F, Poupalos G, et al. Leishmaniases in Greece. Am J Trop Med Hyg. 2013;89(5):906-15.  https://doi.org/10.4269/ajtmh.13-0070  PMID: 24062479 
  6. World Health Organization (WHO). Leishmaniasis: background information. A brief history of the disease. Geneva: WHO. [Accessed: 7 Feb 2020]. Available from: http://www.who.int/leishmaniasis/en
  7. Mazeris A, Soteriadou K, Dedet JP, Haralambous C, Tsatsaris A, Moschandreas J, et al. Leishmaniases and the Cyprus paradox. Am J Trop Med Hyg. 2010;82(3):441-8.  https://doi.org/10.4269/ajtmh.2010.09-0282  PMID: 20207870 
  8. EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare). Scientific opinion on canine leishmaniosis. EFSA Journal. 2015;13(4):4075. Available from: https://www.efsa.europa.eu/en/efsajournal/pub/4075#metadata
  9. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000 Res. 2017;6:750.  https://doi.org/10.12688/f1000research.11120.1  PMID: 28649370 
  10. Pan American Health Organization/World Health Organization Regional Office of the Americas (PAHO/WHO). Neglected infectious diseases. Leishmaniasis. Washington, D.C: PAHO/WHO. [Accessed 7 Feb 2020]. Available from: https://www.paho.org/hq/dmdocuments/2017/2017-cha-leishmaniasis-factsheet-work.pdf
  11. World Health Organization (WHO).. Leishmaniasis. Key facts. Geneva: WHO: 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
  12. World Health Organization Regional Office for Europe (WHO/Europe). Leishmaniasis in the WHO European Region. Copenhagen: WHO/Europe. [Accessed 7 Feb 2020]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0007/246166/Fact-sheet-Leishmaniasis-Eng.pdf?ua=1
  13. European Commission. Commission implementing decision (EU) 2018/945/EU of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Official Journal of the European Union. Luxembourg: Publications Office of the European Union. 6 Jul 2018:L 170/1. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX%3A32018D0945&from=EN%29
  14. Eurosurveillance editorial team. Note from the editors: Eurosurveillance special issue on leishmaniasis painting a picture of the situation in Europe. Euro Surveill. 2013;18(29):20529. PMID: 23929115 
  15. Caminopetros J. New epidemiological and experimental data on leishmaniasis in Greece. Medical Athens.1934;43:653-9.
  16. Gkolfinopoulou K, Bitsolas N, Patrinos S, Veneti L, Marka A, Dougas G, et al. Epidemiology of human leishmaniasis in Greece, 1981-2011. Euro Surveill. 2013;18(29):20532.  https://doi.org/10.2807/1560-7917.ES2013.18.29.20532  PMID: 23929118 
  17. Eurostat. NUTS- Nomencalture of territorial units for statistics. Backgroud. Brussels: European Commission. [Accessed: 19 Jun 2020]. Available from: https://ec.europa.eu/eurostat/web/nuts/background
  18. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, et al. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis. 2008;14(7):1013-8.  https://doi.org/10.3201/eid1407.071589  PMID: 18598618 
  19. Martín-Sánchez J, Pineda JA, Morillas-Márquez F, García-García JA, Acedo C, Macías J. Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. Am J Trop Med Hyg. 2004;70(5):545-8.  https://doi.org/10.4269/ajtmh.2004.70.545  PMID: 15155989 
  20. Ibarra-Meneses AV, Carrillo E, Nieto J, Sánchez C, Ortega S, Estirado A, et al. Prevalence of asymptomatic Leishmania infection and associated risk factors, after an outbreak in the south-western Madrid region, Spain, 2015. Euro Surveill. 2019;24(22):1800379.  https://doi.org/10.2807/1560-7917.ES.2019.24.22.1800379  PMID: 31164191 
  21. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(sup1) Suppl 1;3-15.  https://doi.org/10.1179/000349803225002499  PMID: 14678629 
  22. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-8.  https://doi.org/10.1001/jama.2016.16477  PMID: 27792809 
  23. Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect. 2012;18(7):670-6.  https://doi.org/10.1111/j.1469-0691.2011.03674.x  PMID: 21985586 
  24. Lachaud L, Dedet JP, Marty P, Faraut F, Buffet P, Gangneux JP, et al. Surveillance of leishmaniases in France, 1999 to 2012. Euro Surveill. 2013;18(29):20534.  https://doi.org/10.2807/1560-7917.ES2013.18.29.20534  PMID: 23929121 
  25. The United Nations Refugee Agency (UNHCR). Operational portal. Refugee situation. Mediterranean situation, Greece. Geneva: UNHCR. [Accessed: 30 Dec 2018]. Available from: https://data2.unhcr.org/en/situations/mediterranean/location/5179
  26. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951-70.  https://doi.org/10.1016/S0140-6736(18)31204-2  PMID: 30126638 
  27. Cozzarolo C-S, Sironi N, Glaizot O, Pigeault R, Christe P. Sex-biased parasitism in vector-borne disease: Vector preference? PLoS One. 2019;14(5):e0216360.  https://doi.org/10.1371/journal.pone.0216360  PMID: 31048933 
  28. Hellenic Statistical Authority (ELSTAT). Απογραφή Πληθυσμού-Κατοικιών 2011. [Population housing census 2011]. Piraeus: ELSTAT; 2014. Greek. Available from: https://www.statistics.gr/documents/20181/1210503/A1602_SAM01_DT_DC_00_2011_03_F_GR.pdf/e1ac0b1c-8372-4886-acb8-d00a5a68aabe
  29. Tsirigotakis N, Pavlou C, Christodoulou V, Dokianakis E, Kourouniotis C, Alten B, et al. Phlebotomine sand flies (Diptera: Psychodidae) in the Greek Aegean Islands: ecological approaches. Parasit Vectors. 2018;11(1):97.  https://doi.org/10.1186/s13071-018-2680-4  PMID: 29458398 
  30. Fotakis EA, Giantsis IA, Avgerinou A, Kourtidis S, Agathaggelidou E, Kapoula C, et al. Identification of Leishmania species in naturally infected sand flies from refugee camps, Greece. Emerg Infect Dis. 2019;25(2):361-4.  https://doi.org/10.3201/eid2502.181359  PMID: 30346269 
  31. Riley LW. Differentiating epidemic from endemic or sporadic infectious disease occurrence. Microbiol Spectr. 2019;7(4):AME-0007-2019.  https://doi.org/10.1128/microbiolspec.AME-0007-2019  PMID: 31325286 
Surveillance data for human leishmaniasis indicate the need for a sustainable action plan for its management and control, Greece, 2004 to 2018
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Myrsini+Tzani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tzani Myrsini</a>, <a href="/search?value1=Alicia+Barrasa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barrasa Alicia</a>, <a href="/search?value1=Annita+Vakali&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vakali Annita</a>, <a href="/search?value1=Theano+Georgakopoulou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Georgakopoulou Theano</a>, <a href="/search?value1=Kassiani+Mellou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mellou Kassiani</a>, <a href="/search?value1=Danai+Pervanidou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pervanidou Danai</a></span>. Surveillance data for human leishmaniasis indicate the need for a sustainable action plan for its management and control, Greece, 2004 to 2018. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(18):pii=2000159. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.18.2000159" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.18.2000159</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 19 Feb 2020;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Aug 2020 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.18.2000159
/content/10.2807/1560-7917.ES.2021.26.18.2000159
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error